Cited by 885Genetic Neurodegenerative DiseasesMetabolism and Genetic DisordersMitochondrial Function and Pathology

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, Susan E., Bowling, Allen C., Macgarvey, Usha, Baik, M. Jay, Berger, Stephanie C., Muquit, Miratul M. K., Bird, Edward D., Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410410514

Open this paper in CoChat — free account

Abstract

The etiology of the selective neuronal death that occurs in Huntington's disease (HD) is unknown. Several lines of evidence implicate the involvement of energetic defects and oxidative damage in the disease process, including a recent study that demonstrated an interaction between huntingtin protein and the glycolytic enzyme glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH). Using spectrophotometric assays in postmortem brain tissue, we found evidence of impaired oxidative phosphorylation enzyme activities restricted to the basal ganglia in HD brain, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum). Citrate synthase‐corrected complex II‐III activity was markedly reduced in both HD caudate (−29%) and putamen (−67%), and complex IV activity was reduced in HD putamen (−62%). Complex I and GAPDH activities were unaltered in all regions examined. We also measured levels of the oxidative damage product 8‐hydroxydeoxyguanosine (OH 8 dG) in nuclear DNA, and superoxide dismutase (SOD) activity. OH 8 dG levels were significantly increased in HD caudate. Cytosolic SOD activity was slightly reduced in HD parietal cortex and cerebellum, whereas particulate SOD activity was unaltered in these regions. These results further support a role for metabolic dysfunction and oxidative damage in the pathogenesis of HD.

Integrity signals

Registry

Crossref · 10.1002/ana.410410514

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citation
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Self-citation
Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 961
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
Self-citation
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency
Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730
PURIFICATION OF AMINE OXIDASE FROM BEEF PLASMA
Tabor, C. W., Tabor, H., & Rosenthal, S. M. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65591-7 · Cited by 725

Show all 41 references

Research works printed but not linked: 1

Tabor CW, 1954, Amine oxidases, J Biol Chem, 208, 645

Sorted by citations

Items 401–500 of 883

Experimental developments in movement disorders: update on proposed free radical mechanisms
Przedborski, S., & Jackson-Lewis, V. R. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00009 · Cited by 45
Neuroprotective potential of ionotropic glutamate receptor antagonists
Danysz, W., & Parsons, C. G. (2002) · Neurotoxicity Research · doi:10.1080/10298420290015872 · Cited by 45
Ethyl pyruvate ameliorates 3-nitropropionic acid-induced striatal toxicity through anti-neuronal cell death and anti-inflammatory mechanisms
Jang, M., Lee, M. J., & Cho, I. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.01.015 · Cited by 44
Mitochondrial matters of the brain: the role in Huntington’s disease
Turner, C., & Schapira, A. H. V. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9290-y · Cited by 45
Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease
Lin, Y., Chen, C., Soong, B., Wu, Y., Chen, H., Yeh, W.-Y., Wu, D.-R., Lin, Y., Poon, P. W. F., Cheng, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43220 · Cited by 44
Huntington's disease
Ross, C. A., & Margolis, R. L. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00014-1 · Cited by 44
Excitatory Amino Acid Neurotransmission
Zieglgänsberger, W., Parsons, C. G., & Danysz, W. (2005) · Springer eBooks · doi:10.1007/3-540-28082-0_10 · Cited by 47
Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and µ-opioid receptor binding in the basal ganglia
Page, K. J., Besret, L., Jain, M., Monaghan, E., Dunnett, S. B., & Everitt, B. J. (2000) · Experimental Brain Research · doi:10.1007/s002210050016 · Cited by 44
Therapeutic strategies for ketosis induction and their potential efficacy for the treatment of acute brain injury and neurodegenerative diseases
Camberos-Luna, L., & Massieu, L. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104614 · Cited by 44
Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ
Lesort, M. J., Tucholski, J., Zhang, J., & Johnson, G. V. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751951.x · Cited by 43
Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients
Seo, H., Kim, W., & Ole Isacson, A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn211 · Cited by 43
Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria
Puranam, K. L., Wu, G., Strittmatter, W. J., & Burke, J. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.007 · Cited by 44
Biochemical Analysis of Cybrids Expressing Mitochondrial DNA from Contursi Kindred Parkinson's Subjects
Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Binder, D. R., Bennett, J. P., Iorio, G. D., Golbe, L. I., & Parker, W. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7674 · Cited by 43
Targeting cellular energy production in neurological disorders
Baker, S. K., & Tarnopolsky, M. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1655 · Cited by 43
Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease
D’Egidio, F., Castelli, V., Cimini, A., & d’Angelo, M. (2023) · Antioxidants · doi:10.3390/antiox12030571 · Cited by 42
Chronic Arsenic Exposure-Induced Oxidative Stress is Mediated by Decreased Mitochondrial Biogenesis in Rat Liver
Prakāsh, C., & Kumar, V. J. (2016) · Biological Trace Element Research · doi:10.1007/s12011-016-0622-6 · Cited by 42
Metabolism in HD: Still a relevant mechanism?
Duan, W., Jiang, M., & Jin, J. (2014) · Movement Disorders · doi:10.1002/mds.25992 · Cited by 41
Targeted biochemical profiling of brain from Huntington's disease patients reveals novel metabolic pathways of interest
Graham, S. F., Pan, X., Yılmaz, A., Macias, S., Robinson, A., Mann, D. M. A., & Green, B. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.04.012 · Cited by 41
Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains
Sap, K. A., Güler, A. T., Bezstarosti, K., Bury, A. E., Juenemann, K., Demmers, J., & Reits, E. A. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001486 · Cited by 41
Genome instability and loss of protein homeostasis: converging paths to neurodegeneration?
Ainslie, A. P., Huiting, W., Barazzuol, L., & Bergink, S. (2021) · Open Biology · doi:10.1098/rsob.200296 · Cited by 42
N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases
Martínez, M. (2022) · Antioxidants · doi:10.3390/antiox11020416 · Cited by 46
In Vivo NMR Studies of Neurodegenerative Diseases in Transgenic and Rodent Models
Choi, I.-Y., Lee, P., Guilfoyle, D. N., & Helpern, J. A. (2003) · Neurochemical Research · doi:10.1023/a:1023370104289 · Cited by 42
Paradoxical Cellular Effects and Biological Role of the Multifaceted Compound Nordihydroguaiaretic Acid
Hernández‐Damián, J., Andérica‐Romero, A. C., & Pedraza‐Chaverrí, J. (2014) · Archiv der Pharmazie · doi:10.1002/ardp.201400159 · Cited by 41
Identification and Microbial Production of the Raspberry Phenol Salidroside that Is Active against Huntington’s Disease
Kallscheuer, N., Menezes, R., Foito, A., da Silva, M. H., Braga, A., Dekker, W. J. C., Sevillano, D. M., Rosado-Ramos, R., Jardim, C., Oliveira, J., et al. (2018) · PLANT PHYSIOLOGY · doi:10.1104/pp.18.01074 · Cited by 40
Glucose/mitochondria in neurological conditions
Blass, J. P. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)51010-2 · Cited by 40
Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model
Choo, Y. S., Mao, Z., Johnson, G. V. W., & Lesort, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.065 · Cited by 42
A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction
Dai, Y., Wang, H., Lian, A., Li, J., Zhao, G., Hu, S., & Li, B. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.03.001 · Cited by 40
Genomic Instability Associated with p53 Knockdown in the Generation of Huntington’s Disease Human Induced Pluripotent Stem Cells
Tidball, A. M., Neely, M., Chamberlin, R., Aboud, A. A., Kumar, K. K., Han, B., Bryan, M. R., Aschner, M., Ess, K. C., & Bowman, A. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150372 · Cited by 35
Meldonium improves Huntington’s disease mitochondrial dysfunction by restoring peroxisome proliferator‐activated receptor γ coactivator 1α expression
Cristo, F. D., Finicelli, M., Digilio, F. A., Paladino, S., Valentino, A., Scialò, F., D’Apolito, M., Saturnino, C., Galderisi, U., Giordano, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27602 · Cited by 39
Neuroprotective effects of Psoralea corylifolia Linn seed extracts on mitochondrial dysfunction induced by 3-nitropropionic acid
Im, A., Chae, S., Zhang, G. J., & Lee, M. Y. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-370 · Cited by 39
Huntington's disease: progress and potential in the field
Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39
Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress
Lou, S., Lepak, V. C., Eberly, L. E., Roth, B., Cui, W., Zhu, X., Öz, G., & Dubinsky, J. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw138 · Cited by 41
New developments in the isoprostane pathway: identification of novel highly reactive γ‐ketoaldehydes (isolevuglandins) and characterization of their protein adducts
Roberts, L. J., Salomon, R. G., Morrow, J. D., & Brame, C. J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.10.1157 · Cited by 39
Expression and activity of antioxidants in the brain in progressive supranuclear palsy
Cantuti‐Castelvetri, I., Keller-McGandy, C. E., Albers, D. S., Beal, M. F., Vonsattel, J., Standaert, D. G., & Augood, S. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02244-8 · Cited by 39
Self-citation
CNS Redox Homeostasis and Dysfunction in Neurodegenerative Diseases
Goldsteins, G., Hakosalo, V., Jaronen, M., Keuters, M. H., Lehtonen, Š., & Koıstınaho, J. (2022) · Antioxidants · doi:10.3390/antiox11020405 · Cited by 42
Mitochondrial and redox modifications in early stages of Huntington's disease
Lopes, C., Ferreira, I. L., Maranga, C., Beatriz, M., Mota, S. I., Sereno, J., Castelhano, J., Abrunhosa, A., Oliveira, F. P. M., Rosa, M. D., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102424 · Cited by 37
A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases.
Borza, L. R. (2014) · The Medical-Surgical Journal · Cited by 38
Oxidative stress causes DNA triplet expansion in Huntington's disease mouse embryonic stem cells
Jonson, I., Ougland, R., Klungland, A., & Larsen, E. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.08.010 · Cited by 37
Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II
Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38
Diminished stress resistance and defective adaptive homeostasis in age-related diseases
Lomeli, N., Bota, D. A., & Davies, K. J. A. (2017) · Clinical Science · doi:10.1042/cs20160982 · Cited by 39
Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington’s Patients
Corey‐Bloom, J., Haque, A. S., Aboufadel, S., Snell, C. M., Fischer, R. S., Granger, S. W., Granger, D. A., & Thomas, E. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00073 · Cited by 38
Corticotropin-releasing hormone (CRH) alters mitochondrial morphology and function by activating the NF-kB-DRP1 axis in hippocampal neurons
Battaglia, C. R., Cursano, S., Calzia, E., Catanese, A., & Boeckers, T. M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03204-3 · Cited by 38
Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain
Toneff, T., Mende‐Mueller, L., Wu, Y. N., Hwang, S., Bundey, R. A., Thompson, L. M., Chesselet, M., & HOOK, V. Y. H. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00940.x · Cited by 38
Lamotrigine Is Neuroprotective in the Energy Deficiency Model of MPTP Intoxicated Mice
Lagrue, E., Chalon, S., Bodard, S., Saliba, É., Gressèns, P., & Castelnau, P. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e31806790d7 · Cited by 38
Oxidizing Effects of Exogenous Stressors in Huntington’s Disease Knock-in Striatal Cells—Protective Effect of Cystamine and Creatine
Ribeiro, M., da Silva, A. B. G., Rodrigues, J., Naia, L., & Rego, A. C. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft199 · Cited by 37
Reduction in the E2k Subunit of the α-Ketoglutarate Dehydrogenase Complex Has Effects Independent of Complex Activity
Shi, Q., Chen, H., Xu, H., & Gibson, G. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409064200 · Cited by 38
Trichilia catigua (Catuaba) bark extract exerts neuroprotection against oxidative stress induced by different neurotoxic agents in rat hippocampal slices
Kamdem, J. P., Olalekan, E. O., Hassan, W., Kade, I. J., Ogunbolude, Y., Boligon, A. A., Athayde, M. L., Souza, D. O., & da Rocha, J. B. T. (2013) · Industrial Crops and Products · doi:10.1016/j.indcrop.2013.07.033 · Cited by 37
High sensitivity detection of salivary 8‐hydroxy deoxyguanosine levels in patients with chronic periodontitis
Kurgan, Ş., Önder, C., ALTINGÖZ, S. M., Bağış, N., Uyanık, M., Serdar, M. A., & Kantarcı, A. (2015) · Journal of Periodontal Research · doi:10.1111/jre.12263 · Cited by 37
Targeting Mitochondrial Network Disorganization is Protective in C. elegans Models of Huntington’s Disease
Machiela, E., Rudich, P. D., Traa, A., Anglas, U., Soo, S. K., Senchuk, M. M., & Raamsdonk, J. M. V. (2021) · Aging and Disease · doi:10.14336/ad.2021.0404 · Cited by 34
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain
Bizat, N., Galas, M., Jacquard, C., Boyer, F., Hermel, J., Schiffmann, S. N., Hantraye, P., Blum, D. L., & Brouillet, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.030 · Cited by 36
The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy
Rao, S. S., Portbury, S. D., Lago, L., Bush, A. I., & Adlard, P. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-209009 · Cited by 36
RETRACTED: The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy1
Rao, S. S., Portbury, S. D., Lago, L., Bush, A. I., & Adlard, P. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200551 · Cited by 36
Retracted
Cytochrome c oxidase isoform IV‐2 is involved in 3‐nitropropionic acid‐induced toxicity in striatal astrocytes
Singh, S., Misiak, M., Beyer, C., & Arnold, S. (2009) · Glia · doi:10.1002/glia.20864 · Cited by 36
Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease
Lin, Y.-S., Cheng, T.-H., Chang, C.-P., Chen, H., & Chern, Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.02.006 · Cited by 36
Does tissue transglutaminase play a role in Huntington's disease?
Lesort, M. J., Chun, W., Tucholski, J., & Johnson, G. V. W. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00059-6 · Cited by 36
Chapter 28 Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: New answers, new questions
Ross, C. A., Margolis, R. L., Bêcher, M. W., Wood, J. D., Engelender, S., Cooper, J. K., & Sharp, A. H. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64029-7 · Cited by 36
High-level inhibition of mitochondrial complexes III and IV is required to increase glutamate release from the nerve terminal
Kilbride, S. M., Gluchowska, S. A., Telford, J. E., O'Sullivan, C., & Davey, G. P. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-53 · Cited by 35
Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease
Fão, L., & Rego, A. C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8004 · Cited by 37
The nuclear factor kappa B (NF-κB) signaling pathway is involved in ammonia-induced mitochondrial dysfunction
Adlimoghaddam, A., & Albensi, B. C. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.12.008 · Cited by 36
Interplay between Mitochondrial Protein Import and Respiratory Complexes Assembly in Neuronal Health and Degeneration
Needs, H. I., Protasoni, M., Henley, J. M., Prudent, J., Collinson, I. R., & Pereira, G. C. (2021) · Life · doi:10.3390/life11050432 · Cited by 32
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay, S., Yedke, N. G., Rahi, V., Singh, S., Kumar, S., Arora, A., Chandolia, P., Kaur, P., Kumar, M., Koshal, P., et al. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03868-1 · Cited by 36
Genotype‐dependent priming to self‐ and xeno‐cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease
Mormone, E., Matarrese, P., Tinari, A., Cannella, M., Maglione, V., Farrace, M. G., Piacentini, M., Frati, L., Malorni, W., & Squitieri, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03998.x · Cited by 37
Immunochemical crossreactivity of antibodies specific for “advanced glycation endproducts” with “advanced lipoxidation endproducts”
Richter, T., Münch, G. W., Lüth, H., Arendt, T., Kientsch-Engel, R., Stahl, P., Fengler, D., & Kuhla, B. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.04.009 · Cited by 35
Characterization of Cybrid Cell Lines Containing mtDNA from Huntington's Disease Patients
Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Shilling, A. T., Bennett, J. P., Harrison, M. B., & Parker, W. D. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1095 · Cited by 35
Metabolic dysregulation in Huntington's disease: Neuronal and glial perspectives
Chang, C., Wu, C.-W., & Chern, Y. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106672 · Cited by 37
Nucleic acid therapeutics: a focus on the development of aptamers
Jain, S., Kaur, J., Prasad, S., & Roy, I. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1829587 · Cited by 34
Metabolism in Huntington’s disease: a major contributor to pathology
Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 34
BDNF regulates BIM expression levels in 3-nitropropionic acid-treated cortical neurons
Almeida, S., Laço, M., Cunha‐Oliveira, T., Oliveira, C. R., & Rego, A. C. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.006 · Cited by 34
L -kynurenine: metabolism and mechanism of neuroprotection
Robotka, H., Toldi, J., & Vécsei, L. (2008) · Future Neurology · doi:10.2217/14796708.3.2.169 · Cited by 36
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms
Wells, R. G., Neilson, L. E., McHill, A. W., & Hiller, A. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00406-z · Cited by 36
Therapeutic approaches to preventing cell death in Huntington disease
Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 32
Energy dysfunction in Huntington’s disease: insights from PGC-1α, AMPK, and CKB
Ju, T., Lin, Y., & Chern, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1025-2 · Cited by 34
Increased Caspase-2, Calpain Activations and Decreased Mitochondrial Complex II Activity in Cells Expressing Exogenous Huntingtin Exon 1 Containing CAG Repeat in the Pathogenic Range
Majumder, P., Raychaudhuri, S., Chattopadhyay, B., & Bhattacharyya, N. P. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9220-7 · Cited by 33
D1R- and D2R-Medium-Sized Spiny Neurons Diversity: Insights Into Striatal Vulnerability to Huntington’s Disease Mutation
Bergonzoni, G., Döring, J., & Biagioli, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.628010 · Cited by 32
Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction
Costa, C., Tozzi, A., Luchetti, E., Siliquini, S., Belcastro, V., Tantucci, M., Picconi, B., Ientile, R., Calabresi, P., & Pisani, F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.002 · Cited by 33
Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease
Ryu, J. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00214-0 · Cited by 33
Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease.
Pérez‐Navarro, E., Canals, J. M., Ginés, S., & Alberch, J. (2006) · PubMed · doi:10.14670/hh-21.1217 · Cited by 34
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36
Intense exercise potentiates oxidative stress in striatum of reserpine-treated animals
Teixeira, A. M., Reckziegel, P., Müller, L. G., Pereira, R. P., Roos, D. H., da Rocha, J. B. T., & Bürger, M. E. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.11.015 · Cited by 32
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington’s disease
Polyzos, A. A., & McMurray, C. T. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.003 · Cited by 31
The multifaceted role of quercetin derived from its mitochondrial mechanism
Carrillo-Garmendia, A., Pérez, L. A. M., & Regalado‐González, C. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04833-w · Cited by 36
Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease
Perry, G. M., Tallaksen‐Greene, S. J., Kumar, A., Heng, M. Y., Kneynsberg, A., van Groen, T., Detloff, P. J., Albin, R. L., & Lesort, M. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq247 · Cited by 33
Slowing the body slows down time perception
Kock, R. D., Zhou, W., Joiner, W. M., & Wiener, M. (2021) · eLife · doi:10.7554/elife.63607 · Cited by 39
Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington’s Disease
Pradhan, S., Gao, R., Bush, K. M., Zhang, N., Wairkar, Y. P., & Sarkar, P. S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.837576 · Cited by 34
Post-aggregation Oxidation of Mutant Huntingtin Controls the Interactions between Aggregates
Mitomi, Y., Nomura, T., Kurosawa, M., Nukina, N., & Furukawa, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.387035 · Cited by 31
Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation
Garcı́a, O., Almeida, Á., Massieu, L., & Bolaños, J. P. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02851.x · Cited by 31
Metallothionein-III Prevents γ-Ray-induced 8-Oxoguanine Accumulation in Normal and hOGG1-depleted Cells
Jeong, H. G., Youn, C.-K., Cho, H.-J., Kim, S.-H., Kim, M.-H., Kim, H.-B., Chang, I. Y., Lee, Y., Chung, M., & You, H. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402530200 · Cited by 31
Mitochondrial functional alterations in relation to pathophysiology of Huntington’s disease
Pandey, M., Mohanakumar, K. P., & Rajamma, U. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9288-5 · Cited by 30
Modeling mitochondrial dysfunctions in the brain: from mice to men
Breuer, M. E., Willems, P. H. G. M., Rüssel, F. G. M., Koopman, W. J. H., & Smeitink, J. A. M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9375-8 · Cited by 30
A Review on Natural Antioxidants
Rasheed, A., & Azeez, R. F. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82636 · Cited by 30
Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study
Phillips, M. C. L., McManus, E. J., Brinkhuis, M., & Romero-Ferrando, B. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.931636 · Cited by 31
Atorvastatin attenuates mitochondrial toxin‐induced striatal degeneration, with decreasing iNOS/c‐Jun levels and activating ERK/Akt pathways
Lee, S., Chu, K., Park, J., Hong, N. H., Im, W., Kang, L., Han, Z., Jung, K., Kim, M., & Kim, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05044.x · Cited by 31
Altered lactate metabolism in Huntington's disease is dependent on GLUT 3 expression
Solís‐Maldonado, M., Miró, M. P., Acuña, A. I., Covarrubias‐Pinto, A., Loaiza, A., Mayorga-Weber, G. A., Beltrán, F. A., Cepeda, C., Levine, M. S., Concha, I. I., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12837 · Cited by 29
Treadmill exercise rescues mitochondrial function and motor behavior in the CAG140 knock-in mouse model of Huntington's disease
Caldwell, C. C., Petzinger, G. M., Jakowec, M. W., & Cadenas, E. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108907 · Cited by 29
Power Failure of Mitochondria and Oxidative Stress in Neurodegeneration and Its Computational Models
Woo, J., Cho, H., Seol, Y., Kim, S. H., Park, C., Yousefian-Jazi, A., Hyeon, S. J., Lee, J.-H., & Ryu, H. (2021) · Antioxidants · doi:10.3390/antiox10020229 · Cited by 32
Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease
Lee, S., Park, J., Kim, D., Kim, S., Im, W., Kang, L., Jung, S. H., Kim, M.-W., Chu, K., & Kim, M. (2008) · Brain Research · doi:10.1016/j.brainres.2007.11.058 · Cited by 28
Aberrant regulation of choline metabolism by mitochondrial electron transport system inhibition in neuroblastoma cells
Baykal, A. T., Jain, M. R., & Hong Li, A. (2008) · Metabolomics · doi:10.1007/s11306-008-0125-3 · Cited by 29
Reflections on an unsolved problem of biology: the evolution of senescence and death.
Wr, C. (2004) · PubMed · Cited by 29
Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts
Jędrak, P., Krygier, M., Tońska, K., Drozd, M., Kaliszewska, M., Bartnik, E., Sołtan, W., Sitek, E. J., Stanisławska‐Sachadyn, A., Limon, J., et al. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0026-0 · Cited by 30
Emerging chemotherapeutic strategies for Huntington’s disease
Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30

Authors: Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F.
Affiliations: Harvard University (US)
McLean Hospital (US)
Corresponding author: Beal, M. Flint
ORCID: Browne, Susan E.
Beal, M. Flint
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-05
Volume: 41
Issue: 5
Pages: 646-653
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410410514
OpenAlex: W2102430316
Cited by: 885
References: 41
Citations by year: 2026: 14 · 2025: 12 · 2024: 18 · 2023: 17 · 2022: 25 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 31 · 2017: 13 · 2016: 47 · 2015: 31 · 2014: 41 · 2013: 37 · 2012: 46
FWCI: 10.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2717 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: Huntington's disease, oxidative damage, metabolic dysfunction, basal ganglia, selective neuronal vulnerability, oxidative phosphorylation, complex IV activity, complex I, glyceraldehyde-3-phosphate dehydrogenase, huntingtin, 8-hydroxy-2'-deoxyguanosine, superoxide dismutase, caudate nucleus, putamen, postmortem brain
MeSH terms: Basal Ganglia, Cerebellum, Cerebral Cortex, DNA, Glyceraldehyde-3-Phosphate Dehydrogenases, Humans, Huntington Disease, Mitochondria, Oxidation-Reduction, Reference Values, Spectrophotometry, Stress, Physiological, Superoxide Dismutase, NAD(P)H Dehydrogenase (Quinone), In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks